A5102946681- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Pharmaceutical studies and practices
- Erythrocyte Function and Pathophysiology
- Polyomavirus and related diseases
- Pediatric health and respiratory diseases
- Acute Lymphoblastic Leukemia research
- Kruppel-like factors research
- Acute Myeloid Leukemia Research
- Cooperative Communication and Network Coding
- CAR-T cell therapy research
- Cancer Research and Treatments
- Drug-Induced Adverse Reactions
- Systemic Sclerosis and Related Diseases
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Histone Deacetylase Inhibitors Research
- Radiopharmaceutical Chemistry and Applications
University of Missouri
2023-2024
University of Kentucky
2018-2020
Markey Cancer Center
2018-2020
University of Utah
2015
Louisiana State University Health Sciences Center Shreveport
2010-2012
University of Regensburg
2009
Abstract Chronic lymphocytic leukemia (CLL) patients progressively develop an immunosuppressive state. CLL have more plasma IL-10, anti-inflammatory cytokine, than healthy controls. In vitro human cells produce IL-10 in response to BCR cross-linking. We used the transgenic Eμ–T cell oncogene-1 (TCL1) mouse model study role of associated immunosuppression. Eμ-TCL mice spontaneously because a B cell–specific expression oncogene, TCL1. Eμ-TCL1 constitutively which is further enhanced by...
Abstract Chronic lymphocytic leukemia (CLL) is a mature B cell neoplasm with predilection for older individuals. While previous studies have identified epigenetic signatures associated CLL, whether age-related DNA methylation changes modulate CLL relapse remains elusive. In this study, we examined the association between age acceleration and time to in publicly available dataset. profiling of 35 patients prior initiating chemoimmunotherapy was performed using Infinium HumanMethylation450...
Hairy cell leukemia (HCL) is a rare mature B-cell lymphoproliferative disorder and most often presents as classic hairy leukemia. This entity characterized by an indolent course the presence of BRAF V600E mutation. We report case 80-year-old man with history classical who presented fatigue, dizziness, shortness breath, blurring vision, headache. His initial diagnosis was 9 years prior, he received treatments cladribine, pentostatin, rituximab. The workup showed elevated white blood count...
Abstract T-cell dysfunction is a hallmark of B-cell Chronic Lymphocytic Leukemia (CLL), where CLL cells downregulate responses through regulatory molecules including programmed death ligand-1 (PD-L1) and Interleukin-10 (IL-10). Immune checkpoint blockade (ICB) aims to restore function by preventing the ligation inhibitory receptors like PD-1. However, most patients do not respond well this therapy. Thus, we investigated whether IL-10 suppression could enhance antitumor activity ICB. Since...
Introduction We describe a case of alemtuzumab (Campath®) hypersensitivity requiring desensitization within the medical intensive care unit (MICU) in patient with T-cell prolymphocytic leukemia. Case report adopted protocol from Gutierrez-Fernandez et al., which included three aliquots (0.15 mg intravenously (IV), 1.5 IV, and 28.5 IV) given approximately 1 h apart on day followed by full 30 dose IV 3. Unlike prior attempts to administer this patient, she tolerated medication well did not...
Introduction Gray zone lymphoma (GZL) denotes a group of unclassifiable lymphomas, having features intermediate between diffuse large B-cell and classical Hodgkin's lymphoma. First described in 2005 recognized the WHO classification 2008 as mediastinal GZL. Recently, non-mediastinal GZL (NMGZL) was also characterized. Given its rarity new recognition, information on incidence survival is scarce. Methods The SEER (Surveillance, Epidemiology, End Results) registry used to identify patients...
<div>AbstractPurpose:<p>To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT).</p>Experimental Design:<p>We performed retrospective analysis of outcomes 606 CLL who underwent RIC HCT between 2008 2014 reported to the Center International Blood Marrow Transplant...